Kornimate/medical-research-clean huggingface dataset:
the effect of semaglutide on bone turnover in patients with increased risk of bone fracture

Conditions: Osteopenia

Summary: the hypothesis for this study is that the glp-1ra semaglutide has a positive effect on the balance between build-up and degradation as well as the strength of the bones in men and women aged 40-85 years at increased risk of bone fractures. treatment involves injection of semaglutide 1.34 mg/ml once a week or corresponding volume of placebo once a week for 52 weeks. the effect will be measured by bone markers in blood samples, bone scans, bone tissue tests (bone biopsy), and direct bone strength measured by microindentation at the start and end of the study.


Eligibility criteria:
inclusion criteria: * t-score \<-1 in hip or lower back, assessed by dxa scan and / or * low-energy fracture within the last 3 years exclusion criteria: * t-score \<-2.5 in hip or lower back, assessed by dxa scan, although these individuals may be included if they prefer to participate or are not candidates for conventional therapy, e.g., by egfr \<35 or adverse reaction (influenza-like symptoms, allergic reaction, etc.) to, e.g., bisphosphonate therapy * diabetes type 1 and 2 * heart failure similar to nyha class iv * primary hyperparathyroidism * vitamin d deficiency (\<25 nm) (re-test after substitution acceptable) * known disorders affecting bone metabolism, e.g., uncontrolled thyrotoxicosis, severe renal impairment (egfr \<20) or liver function (baseline phosphatase higher than twice upper limit (105 u/l)), rheumatism, celiac disease, hypogonadism, severe copd, hypopituitarism, cushing's disease * antiresorptive or bone anabolic drugs for the last 12 months * use of anabolic steroids in the previous year * history of pancreatitis * allergy to the medicines used * inability to give informed consent * bmi \<20 kg / m2
comparison of two bipolar resector in less than 3cm myoma resection

Conditions: Rate of Complete Resection in a Unique Surgical Time

Summary: hysteroscopic resection of type 0, 1 or 2 myoma is frequent. the more frequent resector used for myoma resection is 26fr hysteroscope. actual miniaturization of resector led to 18.5fr resector with a potential benefit because of less dilatation. these resectors are often used but no scientific evaluation has been performed. hypothesis of this non inferiority trial is that complete resection in a unique surgical time will be comparable with both resectors.

myoma type 0, 1 or 2 are often symptomatic (abnormal uterine bleeding or infertility) and hysteroscopic resections are thus frequent. this management is a minimally invasive surgery. usually, a 26fr resectoscope is used and the main articles on this topic report hysteroscopie resections with a 26fr resectoscope. miniaturization of resector led to decrease in the size of resectors with a potential benefit because of a less important cervical dilatation and then a smaller risk of adverse events and an increase in the number of surgery under local anaesthesia. use of 18.5fr resectors is more and more frequent but, to our knowledge, it has never been evaluated for benefit on cervical dilatation but also for rate of complete resection in one time, surgical length and rate of unbalanced input/output. intuitively, a smaller diameter could led to a less traumatic cervical dilatation but it could also led to an higher risk of incomplete treatment in one time and a longer surgical duration and a more frequent unbalanced input/output. no study compare use of these two resectors (18.5 and 26fr) all the more randomized. with 26fr resector, the rate of complete resection in one time for less than 3cm myoma is around 90%. if this rate is higher with the 18.5fr resector, the risk/benefit balance (including economic evaluation) won't be favorable to this use.

Eligibility criteria:
inclusion criteria: * older than 18 years old * with a type 0,1 or 2 unique myoma requiring surgery exclusion criteria: * no medical care

Keywords: hysteroscopic myomectomy 26fr resector 18.5fr resector
non-invasive method for evaluation of cardiac resynchronization therapy

Conditions: Heart Failure; Pacemaker DDD; Cardiomyopathies; Heart Diseases; Cardiovascular Diseases

Summary: left bundle branch block (lbbb) exists in about 25% of patients with congestive heart failure and is associated with worsened prognosis. cardiac resynchronization therapy (crt) has been one of the most important advancements in the past two decades for patients with lbbb heart failure. however, 30-40% of patients receiving a crt do not benefit from it. in this study, the investigators will test a noninvasive device to evaluate acute effect of crt during implantation and at follow-up crt controls. in addition, echocardiography will be performed during crt turned on and off to visualize the changes in intraventricular flow and functional parameters of the heart.


Eligibility criteria:
inclusion criteria: * patients referred for crt implantation or postoperative control at oslo university hospital based on the european society of cardiology (esc) guidelines (2021), and criteria below: 1. sinus rhythm. 2. new york heart association class ii / iii heart failure on diagnosis and on optimal medical therapy. 3. left bundle branch block. 4. qrs duration ≥ 130 ms. 5. left ventricular ejection fraction ≤ 40%. 6. patients must have echocardiography examination before implantation 7. informed consent obtained from the patient. exclusion criteria: 1. age \ 80 years; 2. ongoing atrial fibrillation; 3. complete atrioventricular block
topical vitamin b12 in chronic plaque psoriasis

Conditions: Chronic Plaque Psoriasis

Summary: objective: to test the efficacy and tolerability of a vitamin b12 cream for the treatment of chronic plaque psoriasis. design: multicenter, double-blind, randomized, placebo-controlled trial.

objective: to test the efficacy and tolerability of a vitamin b12 cream for the treatment of chronic plaque psoriasis. design: multicenter, double-blind, randomized, placebo-controlled trial. setting: ambulatory patients in research or referral centers. patients: volunteer sample of 51 patients with chronic plaque psoriasis. interventions: all patients applied vitamin b12 cream twice daily for 8 weeks to one side of the body and placebo to the other. main outcome measures: modified psoriasis area and severity index (pasi) at weeks 0, 2, 4, 6 and 8. thickness and density of 3 references plaques determined by 20 mhz sonography. assessment of efficiency and tolerability by patients and investigators.

Eligibility criteria:
inclusion criteria: * 18years * chronic plaque psoriasis exclusion criteria: * incapability of vitamin b12 * necessity of systemic therapy * use of other potentially psoriasis modifying drugs

Keywords: plaque psoriasis vitamin b12
pennisetum purpureum in sarcopenia patients

Conditions: Sarcopenia

Summary: the purpose of this study was to investigate the effects of pennisetum purpureum health food supplementation on muscle mass and muscle strength.

all participants performed anthropometric measurements (body height, body weight, bmi, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey before supplementation. participants were assigned to either the experimental (n=20) or placebo (n=20) group according to their body composition, upper arm circumference, and lower thigh circumference. the definition of insufficient muscle mass was based on the asian working group for sarcopenia (awgs) that skeletal muscle mass in extremities by dual-energy x-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women is a necessary condition, and one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than12 seconds. the anthropometric measurements (body height, body weight, bmi, blood pressure, body composition, upper arm circumference, and lower thigh circumference), blood collection (hormones, liver function, and kidney function), exercise test (grip strength and 10-m walking test), as well as questionnaire survey, were collected after 8 weeks and 12 weeks of supplementation.

Eligibility criteria:
inclusion criteria: 1. adult between 18-75 years old 2. skeletal muscle mass in extremities by dual-energy x-ray absorptiometry less than 7.0 kg/m2 in men and less than 5.4 kg/m2 in women 3. one of the following criteria were met: (1) handgrip strength less than 28 kg in men and less than 18 kg in women and (2) 5-time chair stand test over than 12 seconds exclusion criteria: 1. the volunteers have history of cardiovascular, liver, kidney, and diabetes mellitus 2. acute sport injury 3. participated in any clinical trials or experimental research in the last 3 months before our experiment 4. taking supplement during the experimental period 5. did not maintain their regular eating habit or drink alcohol
early feasibility study - edwards apture transcatheter shunt system

Conditions: Heart Failure

Summary: the purpose of this study is to evaluate initial clinical safety, device functionality and effectiveness of the edwards transcatheter atrial shunt system.

the early feasibility study of the edwards transcatheter atrial shunt system is a multi-center, prospective, early feasibility study to evaluate initial clinical safety, device functionality, and effectiveness of the edwards transcatheter atrial shunt system.

Eligibility criteria:
inclusion criteria: * symptomatic heart failure (hf): * nyha class ii with a history of \> ii; iii; or ambulatory iv and * ≥ 1 hf hospital admission; or treatment with iv or oral diuresis within 12 months; or an nt-pro bnp value \> 150 pg./ml in normal sinus rhythm, \> 450 pg./ml in atrial fibrillation, or a bnp value \> 50 pg./ml in normal sinus rhythm, \> 150 pg./ml in atrial fibrillation within the past 6 months prior to study entry. * on stable guideline directed medical therapy (gdmt) for heart failure * at rest: elevated lap (or pcwp) of \> 15 mmhg and lap (or pcwp) exceeds right atrial pressure (rap) by \> 5 mmhg and/or supine ergometer exercise, elevated la (or pcwp) pressure of \> 25 mmhg and la (or pcwp) exceeds right atrial pressure (rap) by \> 10 mmhg * left ventricular ejection fraction (lvef) ≤ 40% * pulmonary vascular resistance (pvr) \< 4.0 wu exclusion criteria: * severe hf: * stage d, non-ambulatory nyha class iv, transplant list * if bmi \< 30, cardiac index \< 2.0 l/min/m2 * if bmi ≥ 30, cardiac index \< 1.8 l/min/m2 * left ventricular end-diastolic diameter (lvedd) \> 8 cm * lvef \< 20% * valve disease: mr \> 3+ or \> moderate ms, tr \> 2+, ar \> 2+ or \> moderate as * mi or therapeutic invasive cardiac procedure \< 3 months * tia, stroke, crt implanted \< 6 months * rv dysfunction \> mild by tte or tapse \< 1.2 or rv size ≥ lv size by tte, or right ventricular fractional area change (rvfac) ≤ 25% * dialysis or renal dysfunction (s-cr \> 2.5 mg/dl or egfr \< 25 ml/min/1.73m2) * 6mwt \ 600m * active endocarditis or infection \< 3 months * mean right atrial pressure (mrap) \> 15 mmhg at rest * body mass index (bmi) ≥ 45 kg/m2
efficacy and safety of polyene phosphatidylcholine in treatment of patients with acute drug-induced liver injury

Conditions: Acute Drug Induced Liver Injury

Summary: the purpose of this study is to explore the efficacy and the safety of polyene phosphatidylcholine injection in patients with acute drug-induced liver injury after 2-4 weeks of treatment.

this study is a phase iv study in subjects with acute drug-induced liver injury. as designed, the study will include a screening period of up to 1 week, 2 to 4 weeks of treatment, and 1 week of safety follow-up. the eligible subjects will randomly be assigned to polyene phosphatidylcholine group or magnesium isoglycyrrhizinate group to receive single-blind treatment with a ratio of 1:1.

Eligibility criteria:
inclusion criteria: * age ≥ 18 and ≤ 75 years, male or female patients * alanine aminotransferase (alt) ≥ 3 x upper limit of normal (uln) and total bilirubin (tbil) ≤ 5 x upper limit of normal (uln) * the roussel uclaf causality assessment method (rucam) score is more than or equal to 6 points. the patients with rucam score of 3-5 needs to be determined by all three investigators that the liver injury is likely to be caused by drugs * the duration of the current liver injury does not exceed 6 months exclusion criteria: * liver injury caused by other diseases, such as viral hepatitis, alcoholic and non-alcoholic fatty liver disease, or autoimmune liver disease * acute liver failure or liver function decompensation, such as hepatic encephalopathy, ascites, albumin is less than 35g / l, the international standardized ratio (inr) of thrombin is more than 1.5 * anemia or thrombocytopenia, hemoglobin is below 80 g/l, platelet count below 50,000 platelets per microliter * serum creatinine is more than 1.5 times uln * severe hypokalemia, severe hypernatremia * patients have severe uncontrolled hypertension * severe diseases of vital organs such as heart, lung, brain, kidney, and gastrointestinal tract * treatment with polyene phosphatidylcholine injection or magnesium isoglycyrrhizinate injection within 5 days before informed consent * allergy or intolerance to benzyl alcohol and study drugs * with no ability to express their complaints, such as mental illness and severe neurosis patient * pregnant or breastfeeding women, fertile women or men are reluctant to use contraception to avoid pregnancy during the trial * participation in another trial within 3 months before informed consent * patients who are considered by the investigator as inappropriate for the trial for other reasons

Keywords: adili
molecular urine tests for prostate cancer

Conditions: Prostate Cancer

Summary: prostate cancer is the second leading cause of cancer related deaths among men in the united states.1 although still controversial, there is growing evidence that early detection will reduce prostate cancer mortality. currently the most useful biomarker to aid in early detection is measurement of serum prostate specific antigen (psa) levels. despite the value of psa it has substantial limitations. to overcome the limitations of total psa testing, there is emerging evidence demonstrating that relevant cancer biomarker can be detected in urine. patients who present to the urology clinic for a radical prostatectomy will be asked to enter this study. after obtaining informed consent, the following exam and specimen collection scheduled will be followed: visit 1 (pre-op): digital rectal exam (dre) - voided urine collection \& serum collection visit 2 (time of prostatectomy): under anesthesia- catheterized urine collection and serum collection visit 3 (approximately 8 days post-prostatectomy): catheterized urine collection visit 4 (approximately 3 months post-prostatectomy): voided urine collection and serum collection some patients will not have the serum collection at visits 1, 2, and 4. the patients will be notified as to whether or not their blood will be drawn during the visits. pre-operative digital rectal exam, urinary catheterization and blood draws are part of standard of care in this patient population with localized prostate cancer. the catheter will be inserted during the time of surgery preparation in the operating room and removed during the post operative clinic appointment.


Eligibility criteria:
inclusion criteria: * those scheduled to undergo radical prostatectomy for the treatment of prostate cancer. exclusion criteria: * minors

Keywords: prostate cancer pca3
clinical study with the rm pressfit vitamys cup in combination with a mathys stem

Conditions: Arthropathy of Hip; Hip Replacement

Summary: the purpose of the study is the evaluation of the clinical and radiological short- to long-term safety and performance of the rm pressfit vitamys cup. the data will be used for an ongoing evaluation of the product safety and performance.

prospective multicenter follow-up study which examines the short- to long-term post-market clinical data on the safety and performance of the rm pressfit vitamys cup. in total 675 participants in 9 clinics are included in this international multicenter study. the primary endpoint of the study is the harris hip score (hhs) 2 years after surgery. the following parameters will be collected during the regular clinical and radiological follow-up: harris hip score, radiographic evaluation and detection of adverse events.

Eligibility criteria:
inclusion criteria: * informed consent form (signed by participant and investigator) * primary implantation * age at inclusion: between 18 and 95 years old * willing to participate in the follow-up exclusion criteria: * missing informed consent form * known or suspected non-compliance (e.g. drug or alcohol abuse) * enrollment of the investigator, his/her family, employees and other dependent persons * patient younger than 18 years old * revision surgery * presence of sepsis or malignant tumors * pregnancy

Keywords: primary osteoarthritis secondary osteoarthritis inflammatory arthritis congenital dysplasia femoral head fracture
lung clearance index (lci) in pediatric patients with obstructive lung disease

Conditions: Asthma; Bronchiectasis; Cystic Fibrosis

Summary: chronic respiratory diseases (crds) affect the airways and other structures of the lungs and thereby lead to ventilation inhomogeneity. the most common crds in children are asthma, bronchiectasis and cystic fibrosis (cf). all three are obstructive diseases. however, while asthma is mostly characterized by obstruction due to bronchoconstriction of the airways, obstruction in bronchiectasis and cf originates primarily from mucus retention due to abnormal airway clearance mechanisms. the nitrogen multiple breath washout test (n2-mbw-test) is a robust and sensitive detector of early pulmonary changes and ventilation inhomogeneity. the minimal cooperation which is required for this test makes it very convenient for use in any age category. research on lci described it as a reliable indicator of obstructive lung disease in pediatric cf patients as from 6 years of age. whether lci is a reliable parameter for early lung disease in asthma children is less clearly demonstrated. no data were found on lci calculated from the n2-mbw-test in children with bronchiectasis.

subjects of all the intervention groups will perform three consecutive nitrogen multiple breath washout tests (n2-mbw-tests) when attending the universitair ziekenhuis brussel (uzb) for their scheduled pulmonology consultation. only the best measurement (based on lci result) will be taken into account when comparing the groups. every subject will be positioned in the same seated position.

Eligibility criteria:
inclusion criteria: * patients with stable asthma * patients with non-cf bronchiectasis * patients with cystic fibrosis * aged 6-17 years * fev1 (%pred) \>50% * written informed consent from the parents or legal guardian exclusion criteria: * unstable disease (e.g. pulmonary exacerbation, acute deterioration, acute asthma crisis) * patients mentally not capable to participate in the study
endeavor™ in pediatric ms

Conditions: Multiple Sclerosis

Summary: this study will examine the feasibility of using an endeavor™ application as a treatment modality for cognitive impairments in the pediatric ms population. participants will be asked to undergo a hour-long baseline evaluation, followed by at-home endeavor™ application sessions. subjects will complete the user experience feedback form weekly on redcap and at the end of the study. they will undergo another hour-long follow-up evaluation at the end of the study.

duration of subject participation in this study is anticipated to take 3-4 months. after consent/assent, participants will complete an one hour-long baseline study visit in-person at the msccc, or through a video visit. during this visit, participants will complete a neuropsychological evaluation and baseline study surveys and get trained on the use of the endeavor™ video game. participants will then be instructed to target a completion of at-home game play 5 days a week, for a total period of 8 weeks, using their own ios mobile device, or a study-provided device if needed, approximately 25-30 minutes each day. subjects will be instructed to complete the user experience feedback form weekly via redcap to assess feasibility and acceptability of endeavor™. at the conclusion of participation, participants will complete an hour long neuropsychological evaluation and end of study user experience feedback form via redcap (in-person at the msccc, or through a telehealth video visit).

Eligibility criteria:
inclusion criteria: * age at enrollment: 12 years 0 months to 22 years 11 months * confirmed diagnosis of multiple sclerosis with onset \< 17 years and 11 months (defined by the 2013 international pediatric ms study group (ipmssg) criteria (krupp, tardieu, amato, banwell, chitnis, dale, ghezzi, hintzen, kornberg, pohl, rostasy, tenembaum, wassmer, \& sclerosis, 2013) and the 2010 mcdonald criteria (polman et al., 2011).) * followed at nyu langone health msccc * expanded disability status scale (edss) score of ≤3.5 exclusion criteria: * previous report of an iq \< 70 * non-english speaking, learned english in the past three years, or learned english after the age of 12 years * neurological disorder (other than ms) with potential to significantly influence cognition (e.g. head injury) * other serious chronic or unstable medical condition (e.g., epilepsy, sickle cell disease, type 1 diabetes) * not willing to comply with all study procedures * insufficient visual and motor ability to carry out academic and cognitive tests * relapse ≤ 2months prior to academic and cognitive data collection * steroid treatment ≤ 1 month prior to academic and cognitive data collection